Hyper-CVAD chemotherapy or autologous stem cell transplantation in patients with peripheral T cell lymphomas: a single centre report.
- Author:
Yang XU
1
;
Xiao-jin WU
;
Ying WANG
;
Zheng-ming JIN
;
Ai-ning SUN
;
De-pei WU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Cyclophosphamide; therapeutic use; Dexamethasone; therapeutic use; Doxorubicin; therapeutic use; Female; Hematopoietic Stem Cell Transplantation; methods; Humans; Lymphoma, T-Cell, Peripheral; drug therapy; therapy; Male; Middle Aged; Retrospective Studies; Vincristine; therapeutic use; Young Adult
- From: Chinese Medical Journal 2012;125(22):4134-4137
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDPeripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy. The place for high-dose chemotherapy and autologous stem cell transplantation (ASCT) in these patients is still not clear. In this study, we presented the outcomes of PTCL patients followed these treatments in our centre.
METHODSWe retrospectively analyzed the outcomes of 39 patients with PTCL received the two treatments between 1999 and 2010.
RESULTSThe 3-year overall survival (OS) of 61.9% and 3-year progression free survival (PFS) of 35.7% were observed in the 39 patient. Twenty-one patients received Hyper-CVAD chemotherapy with 3-year OS of 46.2% and 3-year PFS of 27.9%. Eighteen patients received ASCT with 3-year OS of 70.3% and 3-year PFS of 44.2%. Further analysis revealed that patients with elevated lactate dehydrogenase, at least 2 international prognostic index (IPI) points, and extranodal involvement had a poorer outcome compared with the control group.
CONCLUSIONThese findings might suggest that Hyper-CVAD chemotherapy and ASCT could offer a durable survival benefit for patients with aggressive PTCL.
